N/A N=29 Development and Feasibility of an Incentive Scheme to Promote Walking/Cycling to School
Physical Activity
Primary: Schools Who Accepted to Take Part — 3.3 % schools who accepted to take part
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=78 Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
Cancer
Primary: 2-year Progression-free Survival (PFS) — 79; 75 percentage of participants
Phase 3 N=61 A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Anemia
Primary: Percentage of Participants With Response to Treatment — 50.8 percentage of participants
N/A N=85 Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient
Pectus Excavatum
Primary: Hospital Length of Stay — 3.5; 3.3 days — p=0.55
Phase 4 N=15 Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit
Depression
Primary: Recruitment Feasibility, Defined as the Number of Participants Recruited and Administered a Medication Dose Within 48 Hours of Mechanical Ventilation — 7; 8 participants
Phase 2 N=25 Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy — 11 Participants
Phase 2 N=24 High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
Relapsing-Remitting Multiple Sclerosis
Primary: Event-Free Survival Probability During the 5 Years After Transplant — 0.692 Probability
Phase 2 N=249 An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
Opioid Dependence
Primary: Adverse Events — 36 adverse events
Phase 4 N=18 PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Plaque Psoriasis
Primary: Cmax of Calcitriol Plasma Level — 120.7 pg/mL
Phase 2 N=41 Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Urologic Neoplasm
Primary: Progression Free Survival — 7.6; 16.4 weeks
N/A N=18 FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Secondary Hyperparathyroidism
Primary: Change in FGF-23 Level — 16; 41 percentage change from baseline
N/A N=45 The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Multiple Sclerosis
Primary: Sexual Dysfunction (as Measured by the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) ) — -0.697 units on a scale
N/A N=36 A Randomized Controlled Trial of the Uresta Continence Pessary
Stress Urinary Incontinence
Primary: A 50% Reduction in Pad Test Weight — 12; 4 Participants
Phase 4 N=64 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Polycystic Ovary Syndrome
Primary: Biochemical Assessment of Hyperandrogenism — 0.7; 0.7 Index — p=<.0001
N/A N=70 The Clinical Comparison of Senofilcon A and Stenfilcon A Contact Lenses
Myopia
Primary: Ocular Physiology — 0.13; 0.13; 0.21; 0.15 units on a scale